Literature DB >> 27352782

Microglia Activation and Schizophrenia: Lessons From the Effects of Minocycline on Postnatal Neurogenesis, Neuronal Survival and Synaptic Pruning.

Dragos Inta1,2, Undine E Lang2, Stefan Borgwardt2, Andreas Meyer-Lindenberg1, Peter Gass1.   

Abstract

The implication of neuroinflammation in schizophrenia, sustained by recent genetic evidence, represents one of the most exciting topics in schizophrenia research. Drugs which inhibit microglia activation, especially the classical tetracycline antibiotic minocycline are currently under investigation as alternative antipsychotics. However, recent studies demonstrated that microglia activation is not only a hallmark of neuroinflammation, but plays important roles during brain development. Inhibition of microglia activation by minocycline was shown to induce extensive neuronal cell death and to impair subventricular zone (SVZ) neurogenesis and synaptic pruning in the early postnatal and adolescent rodent brain, respectively. These deleterious effects contrast with the neuroprotective actions of minocycline at adult stages. They are of potential importance for schizophrenia, since minocycline triggers similar pro-apoptotic effects in the developing brain as NMDA receptor (NMDAR) antagonists, known to induce long-term schizophrenia-like abnormalities. Moreover, altered postnatal neurogenesis, recently described in the human striatum, was proposed to induce striatal dopamine dysregulation associated with schizophrenia. Finally, the effect of minocycline on synapse remodeling is of interest considering the recently reported strong genetic association of the pruning-regulating complement factor gene C4A with schizophrenia. This raises the exciting possibility that in conditions of hyperactive synaptic pruning, as supposed in schizophrenia, the inhibitory action of minocycline turns into a beneficial effect, with relevance for early therapeutic interventions. Altogether, these data support a differential view on microglia activation and its inhibition. Further studies are needed to clarify the relevance of these results for the pathogenesis of schizophrenia and the use of minocycline as antipsychotic drug.
© The Author 2016. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  apoptosis; early therapy; minocycline; postnatal neurogenesis; subventricular zone; synaptic pruning

Mesh:

Substances:

Year:  2017        PMID: 27352782      PMCID: PMC5464012          DOI: 10.1093/schbul/sbw088

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  37 in total

Review 1.  The complement system: an unexpected role in synaptic pruning during development and disease.

Authors:  Alexander H Stephan; Ben A Barres; Beth Stevens
Journal:  Annu Rev Neurosci       Date:  2012       Impact factor: 12.449

Review 2.  The potential of minocycline for neuroprotection in human neurologic disease.

Authors:  Daniel Zemke; Arshad Majid
Journal:  Clin Neuropharmacol       Date:  2004 Nov-Dec       Impact factor: 1.592

3.  Minocycline, schizophrenia and GluR1 glutamate receptors.

Authors:  Radmila Manev; Hari Manev
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-11-17       Impact factor: 5.067

4.  Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain.

Authors:  C Ikonomidou; F Bosch; M Miksa; P Bittigau; J Vöckler; K Dikranian; T I Tenkova; V Stefovska; L Turski; J W Olney
Journal:  Science       Date:  1999-01-01       Impact factor: 47.728

5.  Microglia enhance neurogenesis and oligodendrogenesis in the early postnatal subventricular zone.

Authors:  Yukari Shigemoto-Mogami; Kazue Hoshikawa; James E Goldman; Yuko Sekino; Kaoru Sato
Journal:  J Neurosci       Date:  2014-02-05       Impact factor: 6.167

6.  Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice.

Authors:  Shan Zhu; Irina G Stavrovskaya; Martin Drozda; Betty Y S Kim; Victor Ona; Mingwei Li; Satinder Sarang; Allen S Liu; Dean M Hartley; Du Chu Wu; Steven Gullans; Robert J Ferrante; Serge Przedborski; Bruce S Kristal; Robert M Friedlander
Journal:  Nature       Date:  2002-05-02       Impact factor: 49.962

7.  Possible antipsychotic effects of minocycline in patients with schizophrenia.

Authors:  Tsuyoshi Miyaoka; Rei Yasukawa; Hideaki Yasuda; Maiko Hayashida; Takuji Inagaki; Jun Horiguchi
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-10-05       Impact factor: 5.067

8.  Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms.

Authors:  Deanna L Kelly; Kelli M Sullivan; Joseph P McEvoy; Robert P McMahon; Heidi J Wehring; James M Gold; Fang Liu; Dale Warfel; Gopal Vyas; Charles M Richardson; Bernard A Fischer; William R Keller; Maju Mathew Koola; Stephanie M Feldman; Jessica C Russ; Richard S E Keefe; Jennifer Osing; Leeka Hubzin; Sharon August; Trina M Walker; Robert W Buchanan
Journal:  J Clin Psychopharmacol       Date:  2015-08       Impact factor: 3.153

Review 9.  Revisiting doxycycline in pregnancy and early childhood--time to rebuild its reputation?

Authors:  Ruby Cross; Clare Ling; Nicholas P J Day; Rose McGready; Daniel H Paris
Journal:  Expert Opin Drug Saf       Date:  2016-01-25       Impact factor: 4.250

10.  Biological insights from 108 schizophrenia-associated genetic loci.

Authors: 
Journal:  Nature       Date:  2014-07-22       Impact factor: 49.962

View more
  24 in total

1.  Water-Soluble Arginyl-Diosgenin Analog Attenuates Hippocampal Neurogenesis Impairment Through Blocking Microglial Activation Underlying NF-κB and JNK MAPK Signaling in Adult Mice Challenged by LPS.

Authors:  Bangrong Cai; Kyung-Joo Seong; Sun-Woong Bae; Min Suk Kook; Changju Chun; Jin Ho Lee; Won-Seok Choi; Ji-Yeon Jung; Won-Jae Kim
Journal:  Mol Neurobiol       Date:  2019-02-11       Impact factor: 5.590

Review 2.  Drug-gut microbiota interactions: implications for neuropharmacology.

Authors:  Jacinta Walsh; Brendan T Griffin; Gerard Clarke; Niall P Hyland
Journal:  Br J Pharmacol       Date:  2018-06-28       Impact factor: 8.739

Review 3.  Errant gardeners: glial-cell-dependent synaptic pruning and neurodevelopmental disorders.

Authors:  Urte Neniskyte; Cornelius T Gross
Journal:  Nat Rev Neurosci       Date:  2017-09-21       Impact factor: 34.870

Review 4.  Sifting through the surfeit of neuroinflammation tracers.

Authors:  Paul Cumming; Bjorn Burgher; Omkar Patkar; Michael Breakspear; Neil Vasdev; Paul Thomas; Guo-Jun Liu; Richard Banati
Journal:  J Cereb Blood Flow Metab       Date:  2017-12-19       Impact factor: 6.200

Review 5.  A holistic approach to anesthesia-induced neurotoxicity and its implications for future mechanistic studies.

Authors:  Christine N Zanghi; Vesna Jevtovic-Todorovic
Journal:  Neurotoxicol Teratol       Date:  2016-12-28       Impact factor: 3.763

6.  Targeting the Immune System with Pharmacotherapy in Schizophrenia.

Authors:  Jennifer K Melbourne; Benjamin Feiner; Cherise Rosen; Rajiv P Sharma
Journal:  Curr Treat Options Psychiatry       Date:  2017-04-18

7.  Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning.

Authors:  Carl M Sellgren; Jessica Gracias; Bradley Watmuff; Jonathan D Biag; Jessica M Thanos; Paul B Whittredge; Ting Fu; Kathleen Worringer; Hannah E Brown; Jennifer Wang; Ajamete Kaykas; Rakesh Karmacharya; Carleton P Goold; Steven D Sheridan; Roy H Perlis
Journal:  Nat Neurosci       Date:  2019-02-04       Impact factor: 24.884

8.  Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial.

Authors:  Iris E Sommer; Shiral S Gangadin; Lot D de Witte; Sanne Koops; C van Baal; Sabine Bahn; Hemmo Drexhage; N E M van Haren; Wim Veling; R Bruggeman; Peter Martens; Sybren Wiersma; Selene R T Veerman; Koen P Grootens; Nico van Beveren; Rene S Kahn; Marieke J H Begemann
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 9.306

9.  Modulation of Neuropathic Pain by Glial Regulation in the Insular Cortex of Rats.

Authors:  Songyeon Choi; Kyeongmin Kim; Minjee Kwon; Sun Joon Bai; Myeounghoon Cha; Bae Hwan Lee
Journal:  Front Mol Neurosci       Date:  2022-04-13       Impact factor: 6.261

Review 10.  Can FDA-Approved Immunomodulatory Drugs be Repurposed/Repositioned to Alleviate Chronic Pain?

Authors:  Kufreobong E Inyang; Joseph K Folger; Geoffroy Laumet
Journal:  J Neuroimmune Pharmacol       Date:  2021-05-26       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.